SPYRE THERAPEUTICS INC (SYRE) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SYRE • US00773J2024

33.1 USD
-0.46 (-1.37%)
Last: Feb 11, 2026, 11:59 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SYRE. SYRE was compared to 523 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SYRE as it has an excellent financial health rating, but there are worries on the profitability. SYRE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • SYRE had negative earnings in the past year.
  • In the past year SYRE has reported a negative cash flow from operations.
  • In the past 5 years SYRE always reported negative net income.
  • SYRE had a negative operating cash flow in each of the past 5 years.
SYRE Yearly Net Income VS EBIT VS OCF VS FCFSYRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • SYRE has a better Return On Assets (-29.50%) than 67.50% of its industry peers.
  • SYRE's Return On Equity of -32.75% is fine compared to the rest of the industry. SYRE outperforms 74.38% of its industry peers.
Industry RankSector Rank
ROA -29.5%
ROE -32.75%
ROIC N/A
ROA(3y)-83.74%
ROA(5y)-72.23%
ROE(3y)-110.94%
ROE(5y)-93.82%
ROIC(3y)N/A
ROIC(5y)N/A
SYRE Yearly ROA, ROE, ROICSYRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • SYRE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SYRE Yearly Profit, Operating, Gross MarginsSYRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • SYRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SYRE has more shares outstanding
  • Compared to 5 years ago, SYRE has more shares outstanding
  • There is no outstanding debt for SYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SYRE Yearly Shares OutstandingSYRE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SYRE Yearly Total Debt VS Total AssetsSYRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 27.92 indicates that SYRE is not in any danger for bankruptcy at the moment.
  • SYRE has a Altman-Z score of 27.92. This is amongst the best in the industry. SYRE outperforms 91.97% of its industry peers.
  • There is no outstanding debt for SYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 27.92
ROIC/WACCN/A
WACC12.44%
SYRE Yearly LT Debt VS Equity VS FCFSYRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 10.98 indicates that SYRE has no problem at all paying its short term obligations.
  • SYRE's Current ratio of 10.98 is amongst the best of the industry. SYRE outperforms 85.47% of its industry peers.
  • A Quick Ratio of 10.98 indicates that SYRE has no problem at all paying its short term obligations.
  • The Quick ratio of SYRE (10.98) is better than 85.47% of its industry peers.
Industry RankSector Rank
Current Ratio 10.98
Quick Ratio 10.98
SYRE Yearly Current Assets VS Current LiabilitesSYRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 68.81% over the past year.
  • The Revenue for SYRE has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)68.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.97%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, SYRE will show a small growth in Earnings Per Share. The EPS will grow by 3.31% on average per year.
  • Based on estimates for the next years, SYRE will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y49.18%
EPS Next 2Y16.09%
EPS Next 3Y9.17%
EPS Next 5Y3.31%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

SYRE Yearly Revenue VS EstimatesSYRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 2030 2031 2032 2033 500M 1B 1.5B
SYRE Yearly EPS VS EstimatesSYRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SYRE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SYRE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYRE Price Earnings VS Forward Price EarningsSYRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYRE Per share dataSYRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.09%
EPS Next 3Y9.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SYRE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SPYRE THERAPEUTICS INC

NASDAQ:SYRE (2/11/2026, 11:59:08 AM)

33.1

-0.46 (-1.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-26
Inst Owners82.73%
Inst Owner ChangeN/A
Ins Owners6.7%
Ins Owner Change-12.59%
Market Cap2.57B
Revenue(TTM)N/A
Net Income(TTM)-149.00M
Analysts89
Price Target57.56 (73.9%)
Short Float %14.15%
Short Ratio14.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.06%
Min EPS beat(2)-0.17%
Max EPS beat(2)80.3%
EPS beat(4)3
Avg EPS beat(4)32.57%
Min EPS beat(4)-0.17%
Max EPS beat(4)80.3%
EPS beat(8)4
Avg EPS beat(8)-40.91%
EPS beat(12)5
Avg EPS beat(12)-176.02%
EPS beat(16)7
Avg EPS beat(16)-130.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.33%
PT rev (3m)6.07%
EPS NQ rev (1m)13.87%
EPS NQ rev (3m)19.67%
EPS NY rev (1m)1.51%
EPS NY rev (3m)24.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.64
P/tB 5.64
EV/EBITDA N/A
EPS(TTM)-2.33
EYN/A
EPS(NY)-2.76
Fwd EYN/A
FCF(TTM)-2.09
FCFYN/A
OCF(TTM)-2.09
OCFYN/A
SpS0
BVpS5.86
TBVpS5.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.5%
ROE -32.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.74%
ROA(5y)-72.23%
ROE(3y)-110.94%
ROE(5y)-93.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.98
Quick Ratio 10.98
Altman-Z 27.92
F-Score5
WACC12.44%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.97%
EPS Next Y49.18%
EPS Next 2Y16.09%
EPS Next 3Y9.17%
EPS Next 5Y3.31%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-15.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.3%
EBIT Next 3Y-7.49%
EBIT Next 5Y-10.76%
FCF growth 1Y-86.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.19%
OCF growth 3YN/A
OCF growth 5YN/A

SPYRE THERAPEUTICS INC / SYRE FAQ

What is the ChartMill fundamental rating of SPYRE THERAPEUTICS INC (SYRE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SYRE.


What is the valuation status of SPYRE THERAPEUTICS INC (SYRE) stock?

ChartMill assigns a valuation rating of 0 / 10 to SPYRE THERAPEUTICS INC (SYRE). This can be considered as Overvalued.


Can you provide the profitability details for SPYRE THERAPEUTICS INC?

SPYRE THERAPEUTICS INC (SYRE) has a profitability rating of 1 / 10.